癌症患者经导管主动脉瓣介入治疗
随着人口老龄化,癌症合并重度主动脉瓣狭窄(AS)的患病率不断增加。与外科主动脉瓣置换相比,癌症患者接受经导管主动脉瓣介入(TAVI)的主要不良事件通常较低,尤其是有纵隔放疗史者。癌症患者的TAVI手术和短期至中期结局与无癌症者相似,长期结局取决于癌症生存期。
要点
- 癌症患者接受TAVI的主要不良事件通常低于外科主动脉瓣置换,尤其有纵隔放疗史者。
- 癌症患者与无癌症者的TAVI手术及短期至中期结局相似,长期结局取决于癌症生存期。
- 活动性、晚期癌症及特定癌症亚型患者结局更差,需多学科团队评估TAVI适宜性。
核心结论
- 癌症患者接受TAVI的主要不良事件通常低于外科主动脉瓣置换,尤其有纵隔放疗史者。
- 癌症患者与无癌症者的TAVI手术及短期至中期结局相似,长期结局取决于癌症生存期。
主要发现
- 与外科主动脉瓣置换相比,癌症患者接受TAVI的主要不良事件通常较低,尤其有纵隔放疗史者。
- 癌症患者与无癌症者的TAVI手术及短期至中期结局相似。
- 癌症患者的长期结局取决于癌症生存期。
- 活动性、晚期癌症及特定癌症亚型患者结局更差。
临床怎么用
- 癌症患者的TAVI围术期管理需专业技术和与肿瘤科团队的密切协作。
- 决定是否行TAVI需多学科整体评估介入适宜性。
局限性
- 需要进一步临床试验和注册研究以更好地了解该人群的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prevalence of concurrent cancer and severe aortic stenosis (AS) is increasing due to an ageing population. In addition to shared traditional risk factors for AS and cancer, patients with cancer may be at increased risk for AS due to off-target effects of cancer-related therapy, such as mediastinal radiation therapy (XRT), as well as shared non-traditional pathophysiological mechanisms. Compared with surgical aortic valve replacement, major adverse events are generally lower in patients with cancer undergoing transcatheter aortic valve intervention (TAVI), especially in those with history of mediastinal XRT. Similar procedural and short-to-intermediate TAVI outcomes have been observed in patients with cancer as compared with no cancer, whereas long-term outcomes are dependent on cancer survival. Considerable heterogeneity exists between cancer subtypes and stage, with worse outcomes observed in those with active and advanced-stage disease as well as specific cancer subtypes. Procedural management in patients with cancer poses unique challenges and thus requires periprocedural expertise and close collaboration with the referring oncology team. The decision to ultimately pursue TAVI involves a multidisciplinary and holistic approach in assessing the appropriateness of intervention. Further clinical trial and registry studies are needed to better appreciate outcomes in this population.
引用
- Leedy D, Elison DM, Farias F, et al. Transcatheter aortic valve intervention in patients with cancer. Heart. 2023. PMID: 37147132. doi:10.1136/heartjnl-2022-321396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。